That suppression of CD44 is able to deplete heregulin-induced activation of erbB signalling and also depletes HA-promoted erbB2:erbB3 association suggest a potential value of therapeutically targeting CD44 in breast cancer, potentially to improve the effect of current targeted therapies. Here, ERBB2 is linked to breast carcinoma.